{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Neoplasm", "query": { "condition": "Solid Neoplasm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5349, "total_pages": 535, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Neoplasm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T23:38:51.887Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01149720", "title": "Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Tivantinib (ARQ 197) Capsule", "type": "DRUG" }, { "name": "Tivantinib (ARQ 197) Tablet", "type": "DRUG" }, { "name": "Tivantinib (ARQ 197) Capsule D, oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2010-07", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 4, "location_summary": "Santa Monica, California • Fort Myers, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01149720" }, { "nct_id": "NCT00047242", "title": "UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2002-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-08-09", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047242" }, { "nct_id": "NCT00879073", "title": "Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Metastases" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2009-04", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-18", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00879073" }, { "nct_id": "NCT05734066", "title": "Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Ewing Sarcoma", "Relapsed Ewing Sarcoma", "Ewing Sarcoma" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 60, "start_date": "2023-05-23", "completion_date": "2028-04-20", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05734066" }, { "nct_id": "NCT00413322", "title": "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor" ], "interventions": [ { "name": "belinostat", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valerio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2005-09", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2015-07-08", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Portsmouth", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413322" }, { "nct_id": "NCT02528357", "title": "GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3174998", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 141, "start_date": "2015-09-11", "completion_date": "2020-04-29", "has_results": true, "last_update_posted_date": "2021-05-18", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02528357" }, { "nct_id": "NCT05772130", "title": "Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic and Lymphoid System Neoplasm", "Hereditary Malignant Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Personal Contact", "type": "BEHAVIORAL" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2023-02-14", "completion_date": "2026-12-21", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05772130" }, { "nct_id": "NCT05262530", "title": "Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "BNT142", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2022-03-22", "completion_date": "2025-12-22", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262530" }, { "nct_id": "NCT05494762", "title": "Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "BGB-B167", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2022-08-25", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 3, "location_summary": "Duarte, California • New Haven, Connecticut • Nashville, Tennessee", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05494762" }, { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-21T23:38:51.887Z", "location_count": 9, "location_summary": "Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" } ] }